Back to search results

A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Duchenne Muscular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Republican Scientific and Practical Center Mother and Child, Minsk, Belarus

    Contact: Principal Investigator (Irina V. Zhevneronok, Ph.D.)

  • Russian Children's Clinical Hospital, Moscow, Russia

    Contact: Principal Investigator (Svetlana V. Mikhailova, Dr. Med. Sci.)

  • National Medical Research Center for Children, Moscow, Russia

    Contact: Principal Investigator (Lyudmila M. Kuzenkova, Dr. Med. Sci., professor)

  • Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University, Moscow, Russia

    Contact: Principal Investigator (Dmitry V. Vlodavets, Dr. Med. Sci.)

  • Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia

    Contact: Principal Investigator (Vasily M. Suslov, Ph.D.)

  • Regional Children's Clinical Hospital, Yekaterinburg, Russia

    Contact: Principal Investigator (Olga A. Lvova, Dr. Med. Sci.)
Study leads

  • Oksana A. Markova, M.D.

    Study Chair

    AO GENERIUM

View source on ClinicalTrials.gov(opens in a new tab)